Stock Market & Financial Investment News

News Breaks September 24, 2012 06:08 EDT ISIS Isis Pharmaceuticals weakness a buying opportunity, says Piper Jaffray Piper Jaffray views the sell-off Friday in shares of Isis Pharmaceuticals as a buying opportunity and keeps an Overweight rating on the name with an $18 price target. Piper continues to expect the European Medicines Agency to approve KYNAMRO in Homozygous. News For ISIS From The Last 14 Days Check below for free stories on ISIS the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 10, 2013 07:04 EDT ISIS Xenon licenses antisense drug SEN701 from Isis Pharmaceuticals Subscribe for More Information June 6, 2013 07:01 EDT ISIS Isis Pharmaceuticals earns $6M payment from AstraZeneca Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.